Meet the Team

Adrian’s current research includes incentives for new drugs and vaccines to tackle Antimicrobial Resistance, the use of 'risk-sharing' arrangements between health care payers and pharmaceutical companies, including value-based pricing approaches; the economics of pharmacogenetics for health care payers and the pharmaceutical industry; economic issues that affect both R&D for and access to treatments for diseases prevalent in the developing world.

Professor Lotte Steuten is Head of Consulting and Vice President of the Office of Health Economics.

Lotte’s research interest focuses on the development and application of health economic analysis and health technology assessment (HTA), with the aim to accelerate patient access to high value health care services and treatments. She specializes in quantitative methods for estimating and comparing the expected health and economic benefits of new approaches and interventions in disease prevention, diagnostics and treatment, and prioritizing data collection to efficiently build the evidence for new interventions.

Amanda’s current research interests include the use of real world evidence to support HTA and product development; novel pricing and reimbursement mechanisms for pharmaceuticals (e.g. managed entry agreements and the economics of indication-based pricing); health state valuation methodology; criteria for the economic evaluation of health interventions; and the interaction between HTA policy and optimal R&D decisions by industry

Charlotte joined OHE at the end of 2018 to take up the new role of Project Manager. Her role involves the planning and smooth execution of OHE research projects as well as supporting the overall growth of OHE.

Martina’s current research includes economic issues posed by the development and provision of treatments for rare diseases; the economics of personalised medicine for health care payers and the pharmaceutical industry; and approaches to value based assessments.

Grace’s areas of expertise include health technology appraisal, economic modelling and clinical guidelines. Grace is also interested in the economic evaluation of diagnostics and patient stratification, early stage modelling, and the economic evaluation of regenerative medicines and other high cost therapies. Grace has recently been appointed to NICE’s Clinical Guidelines Update Standing Committee, where she provides expert advice on the economic implications of NICE’s clinical guideline recommendations.

Amy joined OHE at the start of June 2017. Her role involves providing general office support to the team, data collection and reporting at the organisational level, assisting with the production of publications, maintaining the organisations’ website, posting regular updates on social media, and helping co-ordinate promotional activities.

Phill's research interests include the economics of the pharmaceutical market, the productivity and outputs of NICE, and benchmarking industry performance. He has extensive knowledge of, and experience with, data and other information used to understand the medicines market and performance of the pharmaceutical industry.

Koonal's research interests include health state valuation methodology and the use of social value judgements in health care decision making. He has published over 30 journal articles and book chapters on these topics, and has led research and consulting projects for health care providers, research foundations, policy makers and global pharmaceutical companies.